Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: A randomized trial coducted in Chinese patients with nonsmall cell lung cancer

Chinese Medical Journal

Volumn 121, Issue 10, 2008, Pages 892-897

  Liao, Mei Lin ^a   Zhu, Yun Zhong ^b   Li, Long Yun ^c   Wan, Huan Ying ^d   Yu, Shi Ying ^e   Hall, Belinda ^f   West, Teena ^f   Wang, Li ^g  

^a SHANGHAI CHEST HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^e Tongji Hospital   (China)

^f ELI LILLY AUSTRALIA PTY LTD   (Australia)

^g Eli Lilly Asia Inc   (China)

Author keywords

Carcinoma; Chemotherapy; Cisplatin; Gemcitabine; Nonsmall cell lung

Indexed keywords

CISPLATIN; DEXAMETHASONE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 51149119963     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200805020-00006     Document Type: Article

References (18)

1. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005; 14: 243-250.
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
3. Bergman AM, Ruiz Van Haperen VWT, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-530.
4. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuli B, Carrato A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 1999; 17: 12-18.
5. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced nonsmall-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530.
6. Sandler AB, Nemunaitis J, Denham C, Von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2000; 18: 122-130.
7. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002; 346: 92-98.
8. Anton A, Diaz-Fernandez N, Gonzalez Larriba JL, Vadell C, Masutti B, Montalar J, et al. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced nonsmall cell lung cancer (NSCLC). Lung Cancer 1998; 22: 139-148.
9. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced nonsmall-cell lung cancer. J Clin Oncol 1997; 15: 744-749.
10. Comella P. Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced nonsmall cell lung cancer. Semin Oncol 2001; 28 (2 Suppl 7): 7-10.
11. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, et al. Cisplatin-gemcitabine combination in advanced nonsmall-cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
12. Jassem J, Krzakowski M, Roszkowski K, Ramlau R, Slominski JM, Szczesna A, et al. A phase II study of gemcitabine plus cisplatin in patients with advanced nonsmall cell lung cancer: clinical outcomes and quality of life. Lung Cancer 2002; 35: 73-79.
13. Steward WP, Dunlop DJ, Dabouis G, Lacroix H, Talbot D. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced nonsmall cell lung cancer: Preliminary results. Semin Oncol 23 (5 Suppl 10): 43-47.
14. Castellano D, Lianes P, Paz-Ares L, Hidalgo M, Guerra JA, Gomez-Martin C, et al. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced nonsmall-cell lung cancer. Ann Oncol 1998; 9: 457-459.
15. Rinaldi M, Crino L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C, et al. A three week schedule of gemcitabine-cisplatin in advanced nonsmall-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol 2000; 11: 1295-1300.
16. Soto Parra H, Cavina R, Latteri F, Sala A, Dambrosio M, Antonelli G, et al. Three week versus four week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002; 13: 1080-1086.
17. Quoix E, Breton JL, Ducolone A, Mennecier B, Depierre A, Lemarie E, et al. First line chemotherapy with gemcitabine in advanced nonsmall cell lung cancer elderly patients: a randomized phase II study of 3 week versus 4 week schedule. Lung Cancer 2005; 47: 405-412.
18. Wang L, Liao ML, Li LY, Wan HY, Xu N, Liu JW, et al. Clinical benefit of gemcitabine plus cisplatin 3 week regimen for patients with advanced nonsmall cell lung cancer: a prospective observational study. Chin Med J 2004; 117: 1607-1610.